Dashboard
Manage Tickers

AGIO AGIOS PHARMACEUTICALS, INC.


$ 23.11 $ 0.00 (0 %)    

Thursday, 20-Nov-2025 04:14:31 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 609.68 $ 0.00 (0 %)
DIA $ 464.43 $ 0.00 (0 %)
SPY $ 670.66 $ 0.00 (0 %)
TLT $ 88.90 $ 0.00 (0 %)
GLD $ 374.34 $ 0.00 (0 %)
$ na
$ 23.16
$ 22.70 x 109
$ 23.12 x 3
-- - --
$ 22.24 - $ 62.45
17,592,257
na
1.3B
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

crude-oil-falls-over-2-lowes-shares-gain-after-q3-results
Crude Oil Falls Over 2%; Lowe's Shares Gai...
11/19/2025 17:58:53

why-is-agios-pharmaceuticals-stock-sinking-today
Why Is Agios Pharmaceuticals Stock Sinking...
11/19/2025 17:30:29

Agios stock drops as mitapivat's Phase 3 trial shows strong hemoglobin gains but limited impact on sickle cell pain crises,...

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
11/19/2025 17:06:03

agios-pharmaceuticals-says-topline-results-from-rise-up-phase-3-trial-of-mitapivat-for-sickle-cell-disease-met-its-primary-endpoint-of-hemoglobin-response-while-mitapivat-did-not-achieve-statistical-significance-on-the-annualized-rate-of-sickle-cell-pain-crises-compared-to-placebo
Agios Pharmaceuticals Says Topline Results...
11/19/2025 12:06:10

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentrati...

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
11/19/2025 12:05:44

earnings-scheduled-for-october-30-2025
Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

agios-pharmaceuticals-q3-eps-178-beats-191-estimate-sales-12880m-beat-10417m-estimate
Agios Pharmaceuticals Q3 EPS $(1.78) Beats...
10/30/2025 10:35:30

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.78) per share which beat the analyst consensus estimate of...

earnings-outlook-for-agios-pharmaceuticals
Earnings Outlook For Agios Pharmaceuticals
10/29/2025 19:02:33

reported-earlier-agios-pharmaceuticals-receives-chmps-opinion-for-the-new-indication-for-pyrukynd-the-european-commission-will-now-review-the-chmps-opinion-with-the-final-decision-expected-by-early-2026
Reported Earlier: Agios Pharmaceuticals Re...
10/17/2025 15:27:48

CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceut...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/23/2025 12:09:16

hc-wainwright--co-reiterates-buy-on-agios-pharmaceuticals-maintains-56-price-target
HC Wainwright & Co. Reiterates Buy on Agio...
09/04/2025 16:04:25

HC Wainwright & Co. analyst Emily Bodnar reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and maintains $56 pri...

fda-delays-decision-on-agios-pharmaceuticals-blood-disorder-drug-for-expanded-use
FDA Delays Decision On Agios Pharmaceutica...
09/04/2025 14:49:53

Agios' Pyrukynd FDA review for thalassemia delayed to Dec. 7, 2025, after REMS submission addressing potential liver injury...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/04/2025 12:08:12

agios-pharmaceuticals-announces-pdufa-goal-date-for-pyrukynd-extended-by-three-months-to-dec-7
Agios Pharmaceuticals Announces PDUFA Goal...
09/04/2025 11:45:50

Core News & Articles
10 Health Care Stocks With Whale Alerts In...
08/21/2025 17:35:27

saudi-food-and-drug-authority-approves-agios-pyrukynd-for-adults-with-thalassemia
Saudi Food And Drug Authority Approves Agi...
08/04/2025 20:22:10

First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines ProgramAgios partnered...

agios-pharmaceuticals-says-it-is-aware-of-the-securities-analyst-report-published-on-august-4-2025-detailing-recent-pyrukynd-data-from-the-us-fda-adverse-event-reporting-system-co-is-committed-to-delivering-safe-effective-treatments-for-patients-with-rare-diseases-and-will-continue-to-follow-our-established-rigorous-pharmacovigilance-processes-separately-on-august-4-2025-the-saudi-food-and-drug-authority-announced-that-it-has-approvedpyrukynd
Agios Pharmaceuticals Says It Is Aware Of ...
08/04/2025 18:53:07

-SEC Filing

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
08/04/2025 17:06:36

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
08/04/2025 12:08:38

agios-pharmaceuticals-q2-eps-193-misses-177-estimate-sales-12455m-beat-9537m-estimate
Agios Pharmaceuticals Q2 EPS $(1.93) Misse...
07/31/2025 10:32:25

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION